benign symmetric lipomatosis associated with protease inhibitors [letter]

NLM AIDSLINE Benign symmetric lipomatosis associated with protease inhibitors [letter] Hengel RL; Watts NB; Lennox JL
March 30, 1998

Lancet. 1997 Nov 29;350(9091):1596. Unique Identifier : AIDSLINE HIV Protease Inhibitors/ADVERSE EFFECTS Indinavir/ADVERSE EFFECTS *Lipomatosis/CHEMICALLY INDUCED

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 CALIFORNIA: Over Half of People Living with AIDS in San Francisco Are Aged 50 or Older THAILAND; UNITED STATES: HIV Drug Can Also Protect Injection Drug Users INDONESIA: Growing HIV/AIDS Awareness in Indonesia's Papua Region UNITED STATES: Many Young Americans Unaware They're Infected with HIV Board to Vote on Condoms in Boston Schools New International Report on HIV Prevention Urges Localized Consideration of Antiretroviral Strategies UNAIDS and Lancet to bring together political and health leaders to shape the debate on the future of global health Cambodia Trains Social Workers to Curb Reliance on Foreign Aid New Hampshire nears approval of medical marijuana law Celebrating 10 years of PEPFAR AZT associated with poorer immunological recovery in people taking first-line HIV treatment in southern Africa TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events Antiretroviral regimen associated with less virological failure among HIV-infected children EUROPE: Second-Generation Protease Inhibitor Faldaprevir Cures up to 80% of Hepatitis C Metro TeenAIDS Honors Booz Allen Hamilton and Abt Associates With Founders Award for a Decade of Investment in DC Youth Ascletis Gains China Market Rights from Janssen to a Clinical Stage HIV Protease Inhibitor Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat New Therapy for the Management of HIV-associated Enteropathy from Entera Health KS-associated IRIS common among people starting HIV therapy in Africa UNITED STATES: Moderate, Excessive or Heavy Alcohol Consumption: Each is Significantly Associated with Increased Mortality in Patients with Chronic Hepatitis C
Information in this article was accurate in March 30, 1998. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.